AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $219.50, giving the company a market capitalization of 387.45B. It carries a P/E multiple of 165.37 and pays a dividend yield of 3.0%.
As of 2025-11-09, AbbVie(ABBV) stock has fluctuated between $217.09 and $220.94. The current price stands at $219.50, placing the stock +1.1% above today's low and -0.6% off the high.
The AbbVie(ABBV)'s current trading volume is 4.65M, compared to an average daily volume of 5.91M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $163.81.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $163.81.
ABBV News
AbbVie Inc. recently reported third-quarter results with sales of US$15.78 billion and net income of US$186 million, announced a quarterly dividend increase to...
UBS analyst Trung Huynh raised the firm’s price target on AbbVie (ABBV) to $220 from $195 and keeps a Neutral rating on the shares. The firm updated its model f...
Piper Sandler analyst David Amsellem raised the firm’s price target on AbbVie (ABBV) to $289 from $284 and keeps an Overweight rating on the shares following qu...
Analyst ratings
61%
of 31 ratingsMore ABBV News
Home Investing Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More Investing Here Are...
DZ Bank downgraded AbbVie (ABBV) to Hold from Buy with a $237 price target Published first on TheFly – the ultimate source for real-time, market-moving breakin...
This member of dividend royalty checks off lots of boxes for investors. You can sometimes immediately know the quality of a product by the group it's in. For e...
AbbVie (NYSE:ABBV) gave investors plenty to talk about this week, reporting quarterly earnings that exceeded forecasts and announcing a 5.5% increase to its div...